Dr Janet Coller

Senior Lecturer

School of Biomedicine

Faculty of Health and Medical Sciences

Eligible to supervise Masters and PhD - email supervisor to discuss availability.

Dr Janet Coller is a Senior Lecturer in the Discipline of Pharmacology, the School of Medicine at the University of Adelaide. She has significant undergraduate teaching (into 6 courses) and administrative duties, including course coordination and Honours program coordination, accounting for 50% of her time. The remaining 50% is spent running her research program in clinical pharmaco- and immuno-genetics as head of the Clinical Pharmacogenomics Laboratory and member of the Cancer Treatment Toxicities Group

My Research
Career
Publications
Supervision
Professional Activities
Contact

Cancer Treatment Toxicities Group

Our group members include undergraduate students, through to Honours and PhD, as well as postdoctoral researchers. We conduct research projects using cell culture models, transgenic rodents, and in patient cohorts (detailed below). Our mission is to improve cancer outcomes through personalising treatment and supportive care.

Available Research Projects

Research Project 1

Title: Gut microbiome composition as a predictive marker for cancer treatment outcomes

Project description: Patients with cancer are at high risk of microbiome dysbiosis (lack of bacterial diversity and/or overabundance of pathogenic species) due to frequent hospital visits, surgery, chemotherapy and radiation treatment, other medications (notably prophylactic antibiotics), changes in diet, and the presence of cancer itself. Having a diverse gut microbiota is considered protective against chemotherapy-induced infections, and pre-clinical work points to bacterial diversity as a key determinant of tumour response, gastrointestinal toxicity, and neuroinflammation. Thus the objective of this project is to explore links between microbiota, inflammatory responses, and chemotherapy treatment outcomes. Research techniques include mouse models of cancer treated with chemotherapy, bacterial gene sequencing, and a patient trial analysing longitudinal changes in microbiome composition following different cancer therapies.

Projects available for: Honours / HDR

Location: Helen Mayo Building

Research project start: Semester 1 and 2

Special requirements: Nil

Research Project 2

Title: Toll-like receptor 4 and cancer treatment toxicities

Project description: Drugs and radiation used to treat cancer commonly cause damage to the normal gastrointestinal lining, leading to adverse symptoms such as intestinal inflammation and ulceration. There are currently no effective preventative strategies and a lack of understanding surrounding the mechanisms initiating damage. Recently, the innate immunity receptor, Toll-like Receptor 4 (TLR4), has been proposed to play a role in cancer therapy-induced gastrointestinal damage. As such, this project will investigate the effects of TLR4 gene deletion, or pharmacological inhibition, on the development of gastrointestinal inflammation in response to chemotherapy. This project will use rodent models treated with irinotecan. Research techniques include histological analysis, immunofluorescence, real time PCR and small animal handling. Results of this study will provide direct evidence of TLR4 signalling in mediating this important side effect of therapy.

Projects available for: Third Year / Honours / HDR

Location: Helen Mayo Building

Research project start: Semester 1 and 2

Special requirements: Nil

Research Project 3

Title: Role of microbial ablation on diarrhoea risk during treatment with EGFR inhibitors for breast cancer

Project description: Breast cancers that overexpress the human epidermal growth factor receptor (HER2) are treated by targeted small molecule inhibitors such as neratinib. HER2 and other members of the growth factor family are also expressed in the intestines, and treatment with neratinib is associated with chronic low-grade enterocolitis. We have developed a rat model in conjunction with our industry partners to explore the relationship between the composition of resident microbes in the intestine and the risk of severe treatment-related diarrhoea. The project will explore how different antibiotics impact the microbiome and how this affects onset and severity of neratinib diarrhoea. Techniques will include histopathology, immunohistochemistry and mucosal barrier permeability analysis.

Projects available for: HDR (PhD and M.Phil)

Location: Helen Mayo Building

Research project start: Semester 1 and 2

Special requirements: Nil

Appointments

Date	Position	Institution name
2015 - ongoing	Senior Lecturer	University of Adelaide
2013 - 2014	Lecturer	University of Adelaide
2008 - 2012	FTT Fricker Research Fellow	University of Adelaide
2004 - 2007	Postdoctoral Researcher	University of Adelaide

Awards and Achievements

Date	Type	Title	Institution Name	Country	Amount
2007	Research Award	Young Tall Poppy Science Award	Australian Institute of Policy Science	Australia	-
2006	Research Award	ASCEPT Mid-Career Best Paper Award	ASCEPT	Australia	-
2004	Research Award	APSA New Investigator Award	Australasian Pharmaceutical Science Association	Australia	-
2002	Research Award	ASCEPT Denis Wade Johnson & Johnson New Investigators Award	ASCEPT	Australia	-

Education

Date	Institution name	Country	Title
2013 - 2013	University of Adelaide	Australia	Graduate Certificate in Education (Higher Education)
1996 - 2000	University of Adelaide	Australia	PhD (Medicine)
1995 - 1995	University of Adelaide	Australia	Bachelor of Science (Honours Pharmacology)
1992 - 1994	University of Adelaide	Australia	Bachelor of Science

Postgraduate Training

Date	Title	Institution	Country
2002 - 2004	NHMRC CJ Martin Research Fellow	University of Adelaide	Australia
2000 - 2002	NHMRC CJ Martin Research Fellow	Dr Margarete Fischer Bosch Institute of Clinical Pharmacology	Germany

Certifications

Date	Title	Institution name	Country
2015	Dangerous Goods Certification	World Courier Aust Pty Ltd	Australia
2014	AQIS Quarantine Approved Premises (Classes 2 to 8) Accreditation	Australian Government Department of Agriculture	Australia
2014	First Aid Certification	St John Ambulance Australia	Australia

Research Interests

Cancer Biology and Clinical Oncology Cardiac, Respiratory and Vascular Health Neuroscience, Behaviour and Brain Health Indigenous and Disadvantaged Health Translational Health Outcomes

Journals

Year	Citation
2024	Alonge, M., Coller, J. K., Reuter, S. E., Jesudason, S., & Sallustio, B. C. (2024). Determining Plasma Tacrolimus Concentrations Using High-Performance LC-MS/MS in Renal Transplant Recipients. Therapeutic Drug Monitoring, 46(1), 49-56. DOI
2023	Crame, E. E., Nourmohammadi, S., Wardill, H. R., Coller, J. K., & Bowen, J. M. (2023). Contribution of TLR4 to colorectal tumor microenvironment, etiology and prognosis. Journal of Cancer Research and Clinical Oncology, 149(7), 3009-3021. DOI Scopus1
2023	Tam, J. S. Y., Coller, J. K., Prestidge, C. A., & Bowen, J. M. (2023). Investigation of TLR4 Antagonists for Prevention of Intestinal Inflammation. Inflammation, 46(1), 103-114. DOI Scopus5 WoS4 Europe PMC3
2023	Tam, J. S. Y., Pei, J. V., Coller, J. K., Prestidge, C. A., & Bowen, J. M. (2023). Structural insight and analysis of TLR4 interactions with IAXO-102, TAK-242 and SN-38: an in silico approach.. In silico pharmacology, 11(1), 1. DOI Europe PMC1
2023	Korver, S. K., Bowen, J. M., Gibson, R. J., Ball, I. A., Secombe, K. R., Wain, T. J., . . . Coller, J. K. (2023). Advanced statistics identification of participant and treatment predictors associated with severe adverse effects induced by fluoropyrimidine-based chemotherapy. Cancer Chemotherapy and Pharmacology, 91(6), 507-521. DOI Scopus1 Europe PMC1
2023	Maddern, A. S., Coller, J. K., Bowen, J. M., & Gibson, R. J. (2023). The Association between the Gut Microbiome and Development and Progression of Cancer Treatment Adverse Effects. Cancers, 15(17), 22 pages. DOI Scopus1 Europe PMC1
2022	Tam, J. S. Y., Crame, E. E., Elz, A. S., Coller, J. K., Wignall, A., Prestidge, C. A., & Bowen, J. M. (2022). Effects of a novel toll-like receptor 4 antagonist IAXO-102 in a murine model of chemotherapy-induced gastrointestinal toxicity. Cancer Chemotherapy and Pharmacology, 90(3), 267-278. DOI Scopus3 WoS1 Europe PMC2
2022	Secombe, K. R., Crame, E. E., Tam, S. Y. J., Wardill, H. R., Gibson, R. J., Coller, J. K., & Bowen, J. M. (2022). Intestinal toll-like receptor 4 knockout alters the functional capacity of the gut microbiome following irinotecan treatment.. Cancer Chemother Pharmacol, 89(2), 275-281. DOI Scopus3 WoS3 Europe PMC3
2021	Bruning, E. E., Coller, J. K., Wardill, H. R., & Bowen, J. M. (2021). Site-specific contribution of Toll-like receptor 4 to intestinal homeostasis and inflammatory disease. Journal of Cellular Physiology, 236(2), 877-888. DOI Scopus22 WoS12 Europe PMC14
2021	Tam, S. Y., Coller, J. K., Hughes, P. A., Prestidge, C. A., & Bowen, J. M. (2021). Toll-like receptor 4 (TLR4) antagonists as potential therapeutics for intestinal inflammation. Indian Journal of Gastroenterology, 40(1), 5-21. DOI Scopus35 WoS26 Europe PMC21
2021	Sallustio, B. C., Noll, B. D., Hu, R., Barratt, D. T., Tuke, S. J., Coller, J. K., . . . Somogyi, A. A. (2021). Tacrolimus dose, blood concentrations and acute nephrotoxicity, but not CYP3A5/ABCB1 genetics, are associated with allograft tacrolimus concentrations in renal transplant recipients. British Journal of Clinical Pharmacology, 87(10), 3901-3909. DOI Scopus14 WoS12 Europe PMC8
2021	Steele, L., Klimas, N., Krengel, M., Quinn, E., Toomey, R., Little, D., . . . Sullivan, K. (2021). Brain–immune interactions as the basis of gulf war illness: Clinical assessment and deployment profile of 1990–1991 gulf war veterans in the gulf war illness consortium (gwic) multisite case-control study. Brain Sciences, 11(9), 17 pages. DOI Scopus15 WoS11 Europe PMC13
2021	Crame, E. E., Bowen, J. M., Secombe, K. R., Coller, J. K., François, M., Leifert, W., & Wardill, H. R. (2021). Epithelial-Specific TLR4 Knockout Challenges Current Evidence of TLR4 Homeostatic Control of Gut Permeability. Inflammatory Intestinal Diseases, 6(4), 1-11. DOI Scopus3 Europe PMC1
2021	Coller, J. K., Tuke, J., Wain, T. J., Quinn, E., Steele, L., Abreu, M., . . . Sullivan, K. (2021). Associations of immune genetic variability with gulf war illness in 1990–1991 gulf war veterans from the gulf war illness consortium (Gwic) multisite case-control study. Brain Sciences, 11(11), 1410-1-1410-7. DOI Scopus3 WoS2 Europe PMC2
2020	Hu, R., Barratt, D. T., Coller, J. K., Sallustio, B. C., & Somogyi, A. A. (2020). No major effect of innate immune genetics on acute kidney rejection in the first 2 weeks post-transplantation. Frontiers in Pharmacology, 10, 1686-1-1686-8. DOI Scopus3 WoS5 Europe PMC1
2020	Secombe, K. R., Van Sebille, Y. Z. A., Mayo, B. J., Coller, J. K., Gibson, R. J., & Bowen, J. M. (2020). Diarrhea Induced by Small Molecule Tyrosine Kinase Inhibitors Compared With Chemotherapy: Potential Role of the Microbiome.. Integr Cancer Ther, 19, 1534735420928493. DOI Scopus30 WoS26 Europe PMC21
2020	Elad, S., Cheng, K. K. F., Lalla, R. V., Yarom, N., Hong, C., Logan, R. M., . . . Zur, E. (2020). MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer, 126(19), 4423-4431. DOI Scopus261 WoS208 Europe PMC129
2019	Secombe, K. R., Coller, J. K., Gibson, R. J., Wardill, H. R., & Bowen, J. M. (2019). The bidirectional interaction of the gut microbiome and the innate immune system: Implications for chemotherapy‐induced gastrointestinal toxicity. International Journal of Cancer, 144(10), 2365-2376. DOI Scopus48 WoS39 Europe PMC24
2019	Fakiha, K., Coller, J., Logan, R., Gibson, R., & Bowen, J. (2019). Amitriptyline prevents CPT-11-induced early-onset diarrhea and colonic apoptosis without reducing overall gastrointestinal damage in a rat model of mucositis. Supportive Care in Cancer, 27(6), 2313-2320. DOI Scopus8 WoS7 Europe PMC6
2019	Korver, S. K., Gibson, R. J., Bowen, J. M., & Coller, J. K. (2019). Toll-like receptor/interleukin-1 domain innate immune signalling pathway genetic variants are candidate predictors for severe gastrointestinal toxicity risk following 5-fluorouracil-based chemotherapy.. Cancer Chemotherapy and Pharmacology, 83(2), 217-236. DOI Scopus4 WoS3 Europe PMC1
2019	Hu, R., Barratt, D. T., Coller, J. K., Sallustio, B. C., & Somogyi, A. A. (2019). Effect of tacrolimus dispositional genetics on acute rejection in the first 2 weeks and estimated glomerular filtration rate in the first 3 months following kidney transplantation. Pharmacogenetics and Genomics, 29(1), 9-17. DOI Scopus8 WoS7 Europe PMC4
2019	Sallustio, B. C., Noll, B. D., Coller, J. K., Tuke, J., Russ, G., & Somogyi, A. A. (2019). Relationship between allograft cyclosporin concentrations and P-glycoprotein expression in the 1st month following renal transplantation. British Journal of Clinical Pharmacology, 85(5), 1015-1020. DOI Scopus4 WoS3 Europe PMC1
2019	Hu, R., Barratt, D. T., Coller, J. K., Sallustio, B. C., & Somogyi, A. A. (2019). Is there a temporal relationship between trough whole blood tacrolimus concentration and acute rejection in the first 14 days after kidney transplantation?. Therapeutic Drug Monitoring, 41(4), 528-532. DOI Scopus5 WoS4 Europe PMC4
2019	Coller, J. K., Ramachandran, J., John, L., Tuke, J., Wigg, A., & Doogue, M. (2019). The impact of liver transplant recipient and donor genetic variability on tacrolimus exposure and transplant outcome. British Journal of Clinical Pharmacology, 85(9), 2170-2175. DOI Scopus12 WoS11 Europe PMC7
2019	Bowen, J. M., Gibson, R. J., Coller, J. K., Blijlevens, N., Bossi, P., Al-Dasooqi, N., . . . Elad, S. (2019). Systematic review of agents for the management of cancer treatment-related gastrointestinal mucositis and clinical practice guidelines. Supportive Care in Cancer, 27(10), 4011-4022. DOI Scopus50 WoS40 Europe PMC25
2019	Tam, S. Y. J., Coller, J. K., Wignall, A., Gibson, R. J., Khatri, A., Barbé, C., & Bowen, J. M. (2019). Intestinal accumulation of silica particles in a rat model of dextran sulfate sodium-induced colitis.. Annals of gastroenterology, 32(6), 584-592. DOI Scopus6 WoS4 Europe PMC3
2018	Hu, R., Barratt, D., Coller, J., Sallustio, B., & Somogyi, A. (2018). CYP3A53 and ABCB1 61A>G significantly influence dose-adjusted trough blood tacrolimus concentrations in the first three months post-kidney transplantation. Basic and Clinical Pharmacology and Toxicology, 123*(3), 320-326. DOI Scopus25 WoS17 Europe PMC11
2018	Md Dom, Z., Coller, J., Carroll, R., Tuke, J., McWhinney, B., Somogyi, A., & Sallustio, B. (2018). Mycophenolic acid concentrations in peripheral blood mononuclear cells are associated with the incidence of rejection in renal transplant recipients. British Journal of Clinical Pharmacology, 84(10), 2433-2442. DOI Scopus14 WoS12 Europe PMC7
2017	Coller, J. K., Bowen, J. M., Ball, I. A., Wardill, H. R., Van Sebille, Y. Z. A., Stansborough, R. L., . . . Gibson, R. J. (2017). Potential safety concerns of TLR4 antagonism with irinotecan: a preclinical observational report. Cancer Chemotherapy and Pharmacology, 79(2), 431-434. DOI Scopus8 WoS7 Europe PMC6
2016	Wardill, H., Bowen, J., Van Sebille, Y., Secombe, K., Coller, J., Ball, I., . . . Gibson, R. (2016). TLR4-dependent claudin-1 internalization and secretagogue-mediated chloride secretion regulate irinotecan-induced diarrhea. Molecular Cancer Therapeutics, 15(11), 2767-2779. DOI Scopus38 WoS33 Europe PMC17
2016	Somogyi, A., Sia, A., Tan, E., Coller, J., Hutchinson, M., & Barratt, D. (2016). Ethnicity-dependent influence of innate immune genetic markers on morphine PCA requirements and adverse effects in postoperative pain. Pain, 157(11), 2458-2466. DOI Scopus22 WoS18 Europe PMC10
2016	Gibson, R., Coller, J., Wardill, H., Hutchinson, M., Smid, S., & Bowen, J. (2016). Chemotherapy-induced gut toxicity and pain: involvement of TLRs. Supportive Care in Cancer, 24(5), 2251-2258. DOI Scopus20 WoS20 Europe PMC10
2016	Wardill, H., Gibson, R., Van Sebille, Y., Secombe, K., Coller, J., White, I., . . . Bowen, J. (2016). Irinotecan-induced gastrointestinal dysfunction and pain are mediated by common TLR4-dependent mechanisms. Molecular Cancer Therapeutics, 15(6), 1376-1386. DOI Scopus102 WoS82 Europe PMC67
2015	Gibson, R. J., Bowen, J. M., & Coller, J. K. (2015). What are the predictive factors in the risk and severity of chemotherapy-induced gastrointestinal toxicity?. Future Oncology, 11(17), 2367-2370. DOI Scopus10 WoS9 Europe PMC9
2015	Coller, J., White, I., Logan, R., Tuke, J., Richards, A., Mead, K., . . . Bowen, J. (2015). Predictive model for risk of severe gastrointestinal toxicity following chemotherapy using patient immune genetics and type of cancer: a pilot study. Supportive Care in Cancer, 23(5), 1233-1236. DOI Scopus18 WoS16 Europe PMC10
2015	Corrigan, F., Wu, Y., Tuke, J., Coller, J., Rice, K., Diener, K., . . . Hutchinson, M. (2015). Alcohol-induced sedation and synergistic interactions between alcohol and morphine: a key mechanistic role for Toll-like receptors and MyD88-dependent signaling. Brain, Behavior, and Immunity, 45, 245-252. DOI Scopus20 WoS17 Europe PMC18
2015	Somogyi, A., Coller, J., & Barratt, D. (2015). Pharmacogenetics of opioid response. Clinical Pharmacology and Therapeutics, 97(2), 125-127. DOI Scopus36 WoS23 Europe PMC20
2015	Li, Y., Jackson, K., Slon, B., Hardy, J., Franco, M., William, L., . . . Somogyi, A. (2015). CYP2B66 allele and age substantially reduce steady-state ketamine clearance in chronic pain patients: impact on adverse effects. British Journal of Clinical Pharmacology*, 80(2), 276-284. DOI Scopus47 WoS37 Europe PMC27
2014	Somogyi, A., Barratt, D., Ali, R., & Coller, J. (2014). Pharmacogenomics of methadone maintenance treatment. Pharmacogenomics, 15(7), 1007-1027. DOI Scopus39 WoS34 Europe PMC28
2014	Westley, I., Coller, J., Ward, M., Evans, A., Morris, R., & Sallustio, B. (2014). A primer extension denaturing high-performance liquid chromatography method for the identification of three ABCC2 genetic polymorphisms. Journal of Liquid Chromatography and Related Technologies, 37(9), 1249-1256. DOI
2014	Mulholland, C., Somogyi, A., Barratt, D., Coller, J., Hutchinson, M., Jacobson, G., . . . Sleigh, J. (2014). Association of innate immune single-nucleotide polymorphisms with the electroencephalogram during desflurane general anaesthesia. Journal of Molecular Neuroscience, 52(4), 497-506. DOI Scopus13 WoS11 Europe PMC8
2014	Md Dom, Z., Noll, B., Coller, J., Somogyi, A., Russ, G., Hesselink, D., . . . Sallustio, B. (2014). Validation of an LC-MS/MS method for the quantification of mycophenolic acid in human kidney transplant biopsies. Journal of Chromatography B, 945-946, 171-177. DOI Scopus21 WoS19 Europe PMC7
2013	Noll, B., Coller, J., Somogyi, A., Morris, R., Russ, G., Hesselink, D., . . . Sallustio, B. (2013). Validation of an LC-MS/MS method to measure tacrolimus in rat kidney and liver tissue and its application to human kidney biopsies. Therapeutic Drug Monitoring, 35(5), 617-623. DOI Scopus31 WoS30 Europe PMC20
2013	Li, Y., Coller, J., Hutchinson, M., Klein, K., Zanger, U., Stanley, N., . . . Somogyi, A. (2013). The CYP2B66 allele significantly alters the N-demethylation of ketamine enantiomers in vitro. Drug Metabolism and Disposition*, 41(6), 1264-1272. DOI Scopus40 WoS34 Europe PMC21
2012	Coller, J., Michalakas, J., James, H., Farquharson, A., Colvill, J., White, J., & Somogyi, A. (2012). Inhibition of CYP2D6-mediated tramadol O-demethylation in methadone but not buprenorphine maintenance patients. British Journal of Clinical Pharmacology, 74(5), 835-841. DOI Scopus21 WoS16 Europe PMC9
2012	Barratt, D., Coller, J., Hallinan, R., Byrne, A., White, J., Foster, D., & Somogyi, A. (2012). ABCB1 haplotype and OPRM1 118A > G genotype interaction in methadone maintenance treatment pharmacogenetics. Pharmacogenomics and Personalized Medicine, 5(1), 53-62. DOI Scopus47 WoS42 Europe PMC25
2012	Gelston, E., Coller, J., Lopatko, O., James, H., Schmidt, H., White, J., & Somogyi, A. (2012). Methadone inhibits CYP2D6 and UGT2B7/2B4 in vivo: a study using codeine in methadone- and buprenorphine-maintained subjects. British Journal of Clinical Pharmacology, 73(5), 786-794. DOI Scopus25 WoS18 Europe PMC16
2012	Coller, J., & Hutchinson, M. (2012). Implications of central immune signaling caused by drugs of abuse: Mechanisms, mediators and new therapeutic approaches for prediction and treatment of drug dependence. Pharmacology & Therapeutics, 134(2), 219-245. DOI Scopus147 WoS129 Europe PMC109
2012	Wu, Y., Lousberg, E., Moldenhauer, L., Hayball, J., Coller, J., Rice, K., . . . Hutchinson, M. (2012). Inhibiting the TLR4-MyD88 signalling cascade by genetic or pharmacological strategies reduces acute alcohol-induced sedation and motor impairment in mice. British Journal of Pharmacology, 165(5), 1319-1329. DOI Scopus67 WoS57 Europe PMC52
2011	Noll, B., Coller, J., Somogyi, A., Morris, R., Russ, G., Hesselink, D., . . . Sallustio, B. (2011). Measurement of Cyclosporine A in rat tissues and human kidney transplant biopsies - A method suitable for small (<1 mg) samples. Therapeutic Drug Monitoring, 33(6), 688-693. DOI Scopus15 WoS15 Europe PMC10
2011	Coller, J., Cahill, S., Edmonds, C., Farquharson, A., Longo, M., Minniti, R., . . . White, J. (2011). OPRM1 A118G genotype fails to predict the effectiveness of naltrexone treatment for alcohol dependence. Pharmacogenetics and Genomics (Print Edition), 21(12), 902-905. DOI Scopus39 WoS33 Europe PMC26
2011	Liu, L., Coller, J., Watkins, L., Somogyi, A., & Hutchinson, M. (2011). Naloxone-precipitated morphine withdrawal behavior and brain IL-1β expression: Comparison of different mouse strains. Brain Behavior and Immunity, 25(6), 1223-1232. DOI Scopus53 WoS47 Europe PMC40
2011	Wu, Y., Lousberg, E., Moldenhauer, L., Hayball, J., Robertson, S., Coller, J., . . . Hutchinson, M. (2011). Attenuation of microglial and IL-1 signaling protects mice from acute alcohol-induced sedation and/or motor impairment. Brain Behavior and Immunity, 25(Suppl 1), 155-164. DOI Scopus67 WoS52 Europe PMC43
2010	Helsby, N., Hui, C., Goldthorpe, M., Coller, J., Soh, M., Gow, P., . . . Tingle, M. (2010). The combined impact of CYP2C19 and CYP2B6 pharmacogenetics on cyclophosphamide bioactivation. British Journal of Clinical Pharmacology, 70(6), 844-853. DOI Scopus43 WoS40 Europe PMC30
2009	Coller, J., Beardsley, J., Bignold, J., Li, Y., Merg, F., Sullivan, T., . . . Somogyi, A. (2009). Lack of association between the A118G polymorphism of the mu opioid receptor gene (OPRMI) and opioid defendence: A meta-analysis. Pharmacogenomics and Personalized Medicine, 2(1), 9-19. Scopus27 WoS21
2009	Liu, L., Hutchinson, M., White, J., Somogyi, A., & Coller, J. (2009). Association of IL-1B genetic polymorphisms with an increased risk of opioid and alcohol dependence. Pharmacogenetics and Genomics (Print Edition), 19(11), 869-876. DOI Scopus41 WoS36 Europe PMC29
2009	Coller, J., Christrup, L., & Somogyi, A. (2009). Role of active metabolites in the use of opioids. European Journal of Clinical Pharmacology, 65(2), 121-139. DOI Scopus100 WoS75 Europe PMC51
2008	Coller, J., Barratt, D., & Somogyi, A. (2008). Response to "No influence of ABCB1 haplotypes on methadone dosage requirement". Clinical Pharmacology & Therapeutics, 83(5), 669-670. DOI Scopus3 WoS2
2008	Davies, B., Herbert, M., Coller, J., Somogyi, A., Milne, R., & Sallustio, B. (2008). Steady-state pharmacokinetics of the enantiomers of perhexiline in CYP2D6 poor and extensive metabolizers administered Rac-perhexiline. British Journal of Clinical Pharmacology, 65(3), 347-354. DOI Scopus8 WoS8 Europe PMC6
2008	Buck, M., Coller, J., Murdter, T., Eichelbaum, M., & Knabbe, C. (2008). TGFβ2 and TβRII are valid molecular biomarkers for the antiproliferative effects of tamoxifen and tamoxifen metabolites in breast cancer cells. Breast Cancer Research and Treatment, 107(1), 15-24. DOI Scopus26 WoS23 Europe PMC14
2007	Inglis, S., Herbert, M., Davies, B., Coller, J., James, H., Horowitz, J., . . . Sallustio, B. (2007). Effect of CYP2D6 metabolizer status on the disposition of the (+) and (-) enantiomers of perhexiline in patients with myocardial ischaemia. Pharmacogenetics and Genomics (Print Edition), 17(5), 305-312. DOI Scopus6 WoS7 Europe PMC4
2007	Somogyi, A., Barratt, D., & Coller, J. (2007). Pharmacogenetics of opioids. Clinical Pharmacology & Therapeutics, 81(3), 429-444. DOI Scopus285 WoS240 Europe PMC165
2007	Davies, B., Coller, J., Somogyi, A., Milne, R., & Sallustio, B. (2007). CYP2B6 CYP2D6 and CYP3A4 catalyze the primary oxidative metabolism of perhexiline enantiomers by human liver microsomes. Drug Metabolism and Disposition, 35(1), 128-138. DOI Scopus22 WoS21 Europe PMC15
2007	Coller, J., Joergensen, C., Foster, D., James, H., Gillis, D., Christrup, L., & Somogyi, A. (2007). Lack of influence of CYP2D6 genotype on the clearance of (R)- (S)- and racemic-methadon. International Journal of Clinical Pharmacology and Therapeutics, 45(7), 410-417. DOI Scopus25 WoS22 Europe PMC16
2006	Coller, J., Barratt, D., Dahlen, K., Loennechen, M., & Somogyi, A. (2006). ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals. Clinical Pharmacology & Therapeutics, 80(6), 682-690. DOI Scopus128 WoS110 Europe PMC90
2006	Davies, B., Herbert, M., Coller, J., Somogyi, A., Milne, R., & Sallustio, B. (2006). Determination of the 4-monohydroxy metabolites of perhexiline in human plasma, urine and liver microsomes by liquid chromatography. Journal of Chromatography. B, Analytical Techniques in the Biomedical and Life Sciences, 843(2), 302-309. DOI Scopus9 WoS10 Europe PMC3
2006	Barratt, D., Coller, J., & Somogyi, A. (2006). Association between the DRD2 A(1) allele and response to methadone and buprenorphine maintenance treatments. American Journal of Medical Genetics. Part B: Neuropsychiatric Genetics, 141B(4), 323-331. DOI Scopus44 WoS43 Europe PMC39
2006	Davies, B., Herbert, M., Culbert, J., Pyke, S., Coller, J., Somogyi, A., . . . Sallustio, B. (2006). Enantioselective assay for the determination of perhexiline enantiomers in human plasma by liquid chromatography. Journal of Chromatography. B, Analytical Techniques in the Biomedical and Life Sciences, 832(1), 114-120. DOI Scopus17 WoS15 Europe PMC8
2006	Coller, J. K., Plevin, D., Sallustio, B. C., Somogyi, A. A., & Morris, R. G. (2006). Relationship between the ABCB1 genetic polymorphism and clinical outcomes in renal transplant patients.. ACTA PHARMACOLOGICA SINICA, 27, 229.
2005	Davies, B., Coller, J., James, H., Somogyi, A., Horowitz, J., & Sallustio, B. (2005). The influence of CYP2D6 genotype on trough plasma perhexiline and cis-OH-perhexiline concentrations following a standard loading regimen in patients with myocardial ischaemia. British Journal of Clinical Pharmacology, 61(3), 321-325. DOI Scopus10 WoS11 Europe PMC6
2004	James, H., Coller, J., Gillis, D., Bahnisch, J., Sallustio, B., & Somogyi, A. (2004). A new simple diagnostic assay for the identification of the major CYP2D6 genotypes by DNA sequencing analysis. International Journal of Clinical Pharmacology and Therapeutics, 42(12), 719-723. DOI Scopus19 WoS15 Europe PMC11
2004	Davies, B., Coller, J., James, H., Gillis, D., Somogyi, A., Horowitz, J., . . . Sallustio, B. (2004). Clinical inhibition of CYP2D6-catalysed metabolism by the antianginal agent perhexiline. British Journal of Clinical Pharmacology, 57(4), 456-463. DOI Scopus6 WoS6 Europe PMC5
2004	Hutchinson, M., Menelaou, A., Foster, D., Coller, J., & Somogyi, A. (2004). CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes. British Journal of Clinical Pharmacology, 57(3), 287-297. DOI Scopus130 WoS96 Europe PMC64
2004	Coller, J., Krebsfaenger, N., Klein, K., Wolbold, R., Nussler, A., Neuhaus, P., . . . Murdter, T. (2004). Large interindividual variability in the in vitro formation of tamoxifen metabolites related to the development of genotoxicity. British Journal of Clinical Pharmacology, 57(1), 105-111. DOI Scopus31 WoS25 Europe PMC13
2003	Coller, J. (2003). Oxidative metabolism of tamoxifen to Z-4-hydroxy-tamoxifen by cytochrome P450 isoforms: An appraisal of in vitro studies. Clinical and Experimental Pharmacology and Physiology, 30(11), 845-848. DOI Scopus19 WoS19 Europe PMC13
2003	Sallustio, B., Davies, B., Coller, J., James, H., Gillis, D., & Somogyi, A. (2003). Relationship between CYP2D6 genotype and plasma OH-perhexiline/perhexiline concentration ratio in angina patients.. Therapeutic Drug Monitoring, 25(4), 519.
2002	Coller, J., Krebsfaenger, N., Klein, K., Endrizzi, K., Wolbold, R., Lang, T., . . . Murdter, T. (2002). The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver. British Journal of Clinical Pharmacology, 54(2), 157-167. DOI Scopus121 WoS106 Europe PMC82
2001	Murdter, T., Coller, J., Claviez, A., Schonberger, F., Hofmann, U., Dreger, P., & Schwab, M. (2001). Sensitive and rapid quantification of busulfan in small plasma volumes by liquid chromatography-electrospray mass spectrometry. Clinical Chemistry, 47(8), 1437-1442. DOI Scopus42 Europe PMC22
2001	Coller, J., Fritz, P., Zanger, U., Siegle, I., Eichelbaum, M., Kroemer, H., & Murdter, T. (2001). Distribution of microsomal epoxide hydrolase in humans: An immunohistochemical study in normal tissues, and benign and malignant tumours. Journal of Molecular Histology, 33(6), 329-336. DOI Scopus43 WoS42 Europe PMC30
1999	Coller, J., Somogyi, A., & Bochner, F. (1999). Flunitrazepam oxidative metabolism in human liver microsomes: involvement of CYP2C19 and CYP3A4. Xenobiotica, 29(10), 973-986. DOI Scopus33 WoS29 Europe PMC20
1999	Coller, J., Somogyi, A., & Bochner, F. (1999). Comparison of (S)-mephenytoin and proguanil oxidation in vitro: contribution of several CYP isoforms.. British Journal of Clinical Pharmacology, 48(2), 158-167. DOI Scopus42 WoS34 Europe PMC27
1998	Coller, J. K., Somogyi, A. A., & Bochner, F. (1998). Flunitrazepam oxidative metabolism in human liver microsomes. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 358(1), R421.
1998	Coller, J., Somogyi, A., & Bochner, F. (1998). Quantification of flunitrazepam's oxidative metabolites, 3-hydroxyflunitrazepam and desmethylflunitrazepam, in hepatic microsomal incubations by high performance liquid chromatography.. Journal of Chromatography B.., 719(1-2), 87-92. DOI Scopus12 WoS11 Europe PMC3
1997	Coller, J., Somogyi, A., & Bochner, F. (1997). Association between CYP2C19 genotype and proguanil oxidative polymorphism.. British Journal of Clinical Pharmacology, 43(6), 659-660. DOI Scopus21 WoS18 Europe PMC12

Book Chapters

Year	Citation
2016	Coller, J., Barratt, D., & Somogyi, A. (2016). Clinically significant interactions with anti-addiction agents. In M. Jann, S. Penzak, & L. Cohen (Eds.), Applied Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Agents (pp. 565-577). Switzerland: Spinger. DOI
2012	Somogyi, A., & Coller, J. (2012). Drugs against acute and chronic pain. In P. Anzenbacher, & U. Zanger (Eds.), Metabolism of Drugs and Other Xenobiotics (1 ed., pp. 403-428). Germany: Wiley. DOI Scopus3
2008	Somogyi, A., & Coller, J. (2008). Pharmacogenomics and Pharmacogenetics. In An Integrated Compendium of Twenty Encyclopedias (pp. 1-20). United Kingdom: Eolss Publishers.

Conference Papers

Year	Citation
2018	Korver, S. K., Bowen, J. M., Ball, I. A., Gibson, R. J., Tuke, J., Logan, R., . . . Coller, J. K. (2018). Personalised supportive care for patients receiving 5-fluorouracil (5-FU): analysis of multivariate SNP risk prediction for GI toxicity. In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 14 (pp. 58-59). WILEY.
2016	Hu, R. (2016). CYP3A53 and ABCB1 haplotype 61A-1199G-1236T-2677T/A-3435T are associated with dose-adjusted trough blood tacrolimus concentration in kidney transplant recipients. In ASCEPT-MPGPCR 2016*. Melbourne, Australia.
2009	Somogyi, A. A., Gelston, E., Coller, J. K., White, J. M., & Schmidt, H. (2009). Methadone Inhibits CYP2D6 and UGT2B7 <i>In Vivo</i>: a Study using Codeine as the Substrate. In DRUG METABOLISM REVIEWS Vol. 41 (pp. 45-46). Lisbon, PORTUGAL: TAYLOR & FRANCIS INC. WoS1
2009	Sallustio, B. C., Westley, I. S., Coller, J. K., Ward, M. B., Russ, G. R., & Morris, R. G. (2009). Frequency of Genetic Polymorphisms in the Promoter (C-24T), Exon 10 (G1249A) and Exon 28 (C3972T) Regions of <i>ABCC2</i> in Australian Renal Transplant Recipients and Donors. In THERAPEUTIC DRUG MONITORING Vol. 31 (pp. 656-657). Montreal, CANADA: LIPPINCOTT WILLIAMS & WILKINS.
2007	Sallustio, B. C., Davies, B. J., Herbert, M. K., Coller, J. K., Somogyi, A. A., & Milne, R. W. (2007). Steady-state pharmacokinetics of the enantiomers of perhexiline in CYP2D6 extensive and poor metabolisers. In THERAPEUTIC DRUG MONITORING Vol. 29 (pp. 478). Nice, FRANCE: LIPPINCOTT WILLIAMS & WILKINS.

Conference Items

Year	Citation
2019	Coller, J. K., Korver, S. K., Ball, I. A., Gibson, R. J., Tuke, J., Logan, R. M., . . . Bowen, J. M. (2019). Predictors of severe gastrointestinal toxicity risk in patients treated with 5-fluorouracil-based chemotherapy: A validation study. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY.
2017	Korver, S. K., Ball, I. A., Gibson, R. J., Logan, R. M., Karapetis, C. S., Keefe, D. M., . . . Coller, J. K. (2017). The Effect of Immune Genetic Variants on Chemotherapy-Induced Gastrointestinal Toxicity (CIGT) Risk in Patients Receiving 5-Fluorouracil. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY.
2017	Korver, S. K., Ball, I. A., Gibson, R. J., Tuke, J., Logan, R. M., Richards, A., . . . Coller, J. K. (2017). Interleukin-1 Beta (<i>IL1B</i>) Genetic Variability is Predictive of Chemotherapy-Induced Gastrointestinal Toxicity (CIGT) Risk in Patients Receiving 5-Fluorouracil. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY.
2015	Dom, Z. I. M., Westley, I. S., Coller, J. K., Somogyi, A. A., & Sallustio, B. C. (2015). Multidrug Resistance-Associated Protein 2 (MRP2/ABCC2) haplotypes significantly affect the pharmacokinetics of mycophenolic acid in renal transplant recipients. Poster session presented at the meeting of Abstracts of the 2015 Golden Helix Symposium - Next Generation Pharmacogenomics, as published in Public Health Genomics. Karger. DOI WoS1
2014	Li, Y., Coller, J., Hutchinson, M., Klein, K., Zanger, U., Currow, D., . . . Somogyi, A. (2014). Cyp2B66 Allele Alters Ketamine'S Pharmacokinetics In Chronic Pain Patients And Metabolism In Vitro*. Poster session presented at the meeting of Drug Metabolism Reviews. Toronto, CANADA: Informa Healthcare. DOI Europe PMC2
2013	Dom, M. Z., Coller, J. K., Somogyi, A. A., & Sallustio, B. C. (2013). Impact of Recipient and Donor Multidrug Resistance Protein 2 Genetic Variability on Mycophenolic Acid Pharmacokinetics Following Kidney Transplantation. Poster session presented at the meeting of THERAPEUTIC DRUG MONITORING. Salt Lake City, UT: LIPPINCOTT WILLIAMS & WILKINS.
2011	Somogyi, A. A., Coller, J. K., Foster, D. B. F., & Li, Y. (2011). ROLE OF CYP2B6 POLYMORPHISM IN THE METABOLISM AND PHARMACOKINETICS OF METHADONE ENANTIOMERS. Poster session presented at the meeting of BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY. WILEY-BLACKWELL. WoS1

Current Higher Degree by Research Supervision (University of Adelaide)

Date	Role	Research Topic	Program	Degree Type	Student Load	Student Name
2023	Co-Supervisor	Chronic abdominal pain in Australian adolescents and nature-based intervention	Master of Philosophy (Medical Science)	Master	Part Time	Mrs Trish Serocki
2019	Co-Supervisor	Using Pharmacokinetic Principles to Improve the Safety of Tacrolimus in Kidney Transplant Recipients	Doctor of Philosophy	Doctorate	Part Time	Miss Mirabel Alonge

Past Higher Degree by Research Supervision (University of Adelaide)

Date	Role	Research Topic	Program	Degree Type	Student Load	Student Name
2019 - 2023	Co-Supervisor	The Role of TLR4 in Chemotherapy-Induced Toxicity, Immunity and Tumour Growth	Doctor of Philosophy	Doctorate	Full Time	Mrs Elise Ellen Crame
2018 - 2022	Co-Supervisor	Exploring the Effects of Toll-Like Receptor 4 Antagonism on Gastrointestinal Mucositis and Tumour Activity	Doctor of Philosophy	Doctorate	Full Time	Miss Shu Yie Janine Tam
2017 - 2021	Co-Supervisor	Exploration of the gut microbiome as a predictive factor for cancer treatment-induced gastrointestinal toxicity	Doctor of Philosophy	Doctorate	Full Time	Miss Kate Rebecca Secombe
2016 - 2020	Principal Supervisor	Identifying potential genetic, phenotypic and epigenetic predictive markers in the Toll-like receptor/Interleukin-1 domain innate immune signalling pathway for severe gastrointestinal toxicity risk following 5-Fluorouracil-based therapy	Doctor of Philosophy	Doctorate	Full Time	Miss Samantha Kaitlyn Korver
2015 - 2019	Co-Supervisor	Genetics of Tacrolimus Pharmacokinetics and Kidney Transplant Outcomes	Doctor of Philosophy	Doctorate	Full Time	Ms Rong Hu
2011 - 2017	Co-Supervisor	Mycophenolic Acid Pharmacokinetics and Clinical Outcomes in Renal Transplantation: Effect of ABCC2 Haplotype Analysis and Distribution into Lymphocytes and Kidney	Doctor of Philosophy	Doctorate	Full Time	Mr Zaipul Izwan Md Dom
2010 - 2014	Co-Supervisor	Pharmacogenetics of Ketamine Metabolism and Immunopharmacology of Ketamine	Doctor of Philosophy	Doctorate	Full Time	Mr Yibai Li
2010 - 2015	Co-Supervisor	A Study Linking Toll-like Receptors and Irinotecan-induced Gastrointestinal Mucositis	Doctor of Philosophy	Doctorate	Full Time	Mrs Khloud Ghazi Fakiha
2009 - 2011	Co-Supervisor	CNS Immune Signalling and Drug Addiction: Role of Interleukin-1 Beta	Doctor of Philosophy	Doctorate	Full Time	Mr Liang Liu
2008 - 2011	Co-Supervisor	The Neuroimmunopharmacology of Alcohol	Doctor of Philosophy	Doctorate	Full Time	Miss Yue Wu
2005 - 2010	Co-Supervisor	Pharmacogenomics of ABCB1 in Maintenance Pharmacotherapies for Opioid Dependence	Doctor of Philosophy	Doctorate	Full Time	Dr Daniel Barratt
2003 - 2008	Co-Supervisor	The Stereoselective Pharmacokinetics of the Enantiomers of Perhexiline in Poor and Extensive Metabolisers of the Cytochrome P450 2D6	Doctor of Philosophy	Doctorate	Full Time	Mr Benjamin Davies

Memberships

Date	Role	Membership	Country
2016 - ongoing	Member	MASCC	United States
2012 - ongoing	Member	PNIRS	United States
2004 - ongoing	Member	APSA	Australia
1998 - 2015	Member	ISSX	United States
1995 - ongoing	Member	ASCEPT	Australia

Editorial Boards

Date Role Editorial Board Name Institution Country
2012 - ongoing Board Member Frontiers in Pharmacogenetics - -
2007 - 2012 Board Member The Open Drug Metabolism Journal - -

Date	Role	Editorial Board Name	Institution	Country
2012 - ongoing	Board Member	Frontiers in Pharmacogenetics	-	-
2007 - 2012	Board Member	The Open Drug Metabolism Journal	-	-

Position: Senior Lecturer
Phone: 83133906
Email: janet.coller@adelaide.edu.au
Fax: 82240685
Campus: North Terrace
Building: Helen Mayo North, floor 5
Org Unit: Medical Sciences

Dr Janet Coller

Cancer Treatment Toxicities Group

Available Research Projects

Appointments

Awards and Achievements

Education

Postgraduate Training

Certifications

Research Interests

Journals

Book Chapters

Conference Papers

Conference Items

Current Higher Degree by Research Supervision (University of Adelaide)

Past Higher Degree by Research Supervision (University of Adelaide)

Memberships

Editorial Boards

Connect With Me

External Profiles